Lapatinib: Difference between revisions

@@ Line 3: / Line 3: @@
 {| class="wikitable" border="1" width="40%" style="text-align:center"
 |-
-!  colspan="6" align="center"| Glitazone [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>doi: 10.1111/j.1365-2125.2007.02986.x</ref><ref>PMID:18997160</ref><ref>PMID: 9454824</ref><ref>PMID: 17594391</ref>
+!  colspan="6" align="center"| Glitazone [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>PMC:2679105</ref>
 |-
 ! Parameter
@@ Line 11: / Line 11: @@
 |-
 ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
-! Lapatinib (Tykerb)
+! 4
 ! Sunitinib (Sutent)
 ! Sorafenib (Nexavar)
 |-
 ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
-! Lapatinib (Tykerb)
+! 115
 ! Sunitinib (Sutent)
 ! Sorafenib (Nexavar)
@@ Line 31: / Line 31: @@
 |-
 ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
-! Lapatinib (Tykerb)
+! 9.6
 ! Sunitinib (Sutent)
 ! Sorafenib (Nexavar)
 |-
 ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
-! Lapatinib (Tykerb)
+! 1429
 ! Sunitinib (Sutent)
 ! Sorafenib (Nexavar)
@@ Line 45: / Line 45: @@
 ! Sorafenib (Nexavar)
 |-
-! Clearance (ml/hr)
+! Dosage (mg)
-! Lapatinib (Tykerb)
+! 100
-! Sunitinib (Sutent)
-! Sorafenib (Nexavar)
-|-
-! Equivalent Dosage (mg)
-! Lapatinib (Tykerb)
 ! Sunitinib (Sutent)
 ! Sorafenib (Nexavar)

Navigation menu